Angiotensin receptor blockers in diabetic nephropathy: Renal and cardiovascular end points

被引:50
作者
Parving, HH
Andersen, S
Jacobsen, P
Christensen, PK
Rossing, K
Hovind, P
Rossing, P
Tarnow, L
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark
关键词
D O I
10.1016/j.semnephrol.2003.11.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The activity of the renin-angiotensin-aldosterone system (RAAS) is elevated both in the circulation and in the renal tissue of diabetic and nondiabetic nephropathies. The increased RAAS activity plays an important role in the hemodynamic and nonhemodynamic pathogenetic mechanisms involved in kidney disease. Previous studies have demonstrated that albuminuria is not only a marker of glomerular lesions, but also a progression promoter, and finally a powerful predictor of the long-term beneficial effect of blood pressure-lowering therapy. Randomized crossover and parallel blind studies in patients with diabetic nephropathy have demonstrated that angiotensin II receptor blockers (ARB) induce favorable changes in systemic blood pressure, renal hemodynamics, and proteinuria similar to those induced by angiotensin-converting enzyme (ACE) inhibition. Studies have revealed the optimal renoprotective dose for some ARBs; however, additional dose titration studies are urgently needed to obtain the maximum benefit of this valuable new class of compounds. The combination of ARB and ACE inhibition is well tolerated and even more effective than monotherapy in reducing systemic blood pressure and albuminuria in diabetic nephropathy. In addition, dual RAAS blockade is sale and well tolerated. Impaired autoregulation of glomerular filtration rate (GFR); demonstrated with some blood pressure-lowering agents implies disturbances in the downstream transmission of the systemic blood pressure into the glomerulus, leading to capillary hypertension or hypotension depending of the level of blood pressure. ARB does not interfere with GFR autoregulation in hypertensive diabetic patients. In contrast to previous observational studies with ACE inhibition, long-term treatment with ARB has similar beneficial renoprotective effect on progression of diabetic kidney disease in hypertensive diabetic patients with ACE II and DD genotypes. ARB can prevent/delay development of diabetic nephropathy independently of its beneficial blood pressure-lowering effect in patients with type 2 diabetes and microalbuminuria. Recently, two landmark studies led to the following conclusion: Losartan and Irbesartan conferred significant renal benefit in patients with type 2 diabetes and nephropathy. This protection is independent of the reduction in blood pressure it causes. The ARB is generally safe and well tolerated. "A recent metaanalysis indicates that ARBs reduce cardiovascular events mainly because of reduction in first hospitalization for congestive heart failure in hypertensive type 2 diabetic patients with albuminuria. The studies mentioned here suggest that ARB represents a beneficial treatment of hypertension and proteinuria in incipient and overt diabetic nephropathy. © 2004 Elsevier Inc. All rights reserved."
引用
收藏
页码:147 / 157
页数:11
相关论文
共 71 条
[21]   Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients [J].
Christensen, PK ;
Lund, S ;
Parving, HH .
KIDNEY INTERNATIONAL, 2001, 60 (04) :1435-1442
[22]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[23]   Renoprotective therapy: titration against urinary protein excretion [J].
De Jong, PE ;
Navis, G ;
de Zeeuw, D .
LANCET, 1999, 354 (9176) :352-353
[24]  
de Zeeuw D, 2003, DIABETOLOGIA, V46, pA339
[25]   Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].
Gaede, P ;
Vedel, P ;
Larsen, N ;
Jensen, GVH ;
Parving, H ;
Pedersen, O .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393
[26]   ALBUMINURIA AND POOR GLYCEMIC CONTROL PREDICT MORTALITY IN NIDDM [J].
GALL, MA ;
BORCHJOHNSEN, K ;
HOUGAARD, P ;
NIELSEN, FS ;
PARVING, HH .
DIABETES, 1995, 44 (11) :1303-1309
[27]   Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union [J].
Gerth, WC ;
Remuzzi, G ;
Viberti, G ;
Hannedouche, T ;
Martinez-Castelao, A ;
Shahinfar, S ;
Carides, GW ;
Brenner, B .
KIDNEY INTERNATIONAL, 2002, 62 :S68-S72
[28]  
Hilgers KF, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341100
[29]   Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively [J].
Hovind, P ;
Rossing, P ;
Tarnow, L ;
Smidt, UM ;
Parving, HH .
KIDNEY INTERNATIONAL, 2001, 60 (01) :277-283
[30]   Progression of diabetic nephropathy [J].
Hovind, P ;
Rossing, P ;
Tarnow, L ;
Smidt, UM ;
Parving, HH .
KIDNEY INTERNATIONAL, 2001, 59 (02) :702-709